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Objective: Acarbose is a glucosidase inhibitor that slows carbohydrate digestion. It could thus 
be effective to promote remission of dumping syndrome (DS). Previous studies associating 
acarbose and late dumping, although not early dumping, have been reported. Herein, we aimed 
to evaluate the role of acarbose in dumping syndrome prevention and treatment and in resistive 
exercises resistance in bariatric subjects.
Methods: Bariatric patients with DS and complete adherence to diet plan and resistive exercises 
were included (n=25). Number of early and late episodes, self-referred intensity of each episode, 
and ability to increase intensity of resistive exercise were evaluated, on a 0–10 scale. Acarbose 
was administered orally (50 mg) for 6 months, 4–5 times a day before meals.
Results: Acarbose administration was associated with a decrease in the number of early 
(2.18–0.31) and late (2.79–0.12) episodes per week and intensity of each episode (6.10–1.65) 
and an increase in the ability to perform resistive exercises (3.03–7.12). Complete remission 
of DS was seen in 21 patients (84%), which persisted for 6 months with the use of acarbose.
Conclusion: Acarbose prevented dumping in almost all studied subjects and helped improve 
exercise capacity.
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Introduction
Dumping syndrome (DS) is the effect of rapid gastric emptying with consequent 
hyperosmolar jejunal chime, inappropriate gut-hormone release, and rapid glucose 
absorption, and it is particularly common among post-bariatric surgery patients, as it 
occurs in up to 75% of patients after Roux-en-Y gastric bypass surgery.1–5 DS can be 
either early – when symptoms happen between 30 and 60 min as a result of rapid instil-
lation of meals into the small bowel and decreased blood volume due to intraluminal 
fluid sequestration, and most symptoms are abdominal (bloating and abdominal pain) 
and systemic (palpitations, fatigue, tachycardia, lightheadedness, and syncope) – or 
late, which is thought to be caused by hyperinsulinemic hypoglycemia, and the most 
commonly observed symptoms and signs are due to neuroglycopenia and hyperad-
renergic state (decreased consciousness, shakiness, and difficulty to concentrate). It 
is important to note that often patients may present both early and late DS at the same 
meal. DS reduces the quality of life as symptoms are usually severe and can limit 
sports capacity and everyday activities.1–7
Current approaches for DS treatment comprise dietary recommendations3,4,6 such 
as small and frequent meals, inclusion of fiber and protein in every meal, and  ingestion 
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of guar gum and pectin. Pharmacological options for DS are 
limited and mostly symptomatic, such as tincture opium for 
diarrhea,7 meclizine, promethazine, and proton pump inhibi-
tors.3,6 Octreotide has been shown to be markedly effective to 
improve the quality of life in DS,8,9 despite commercial and 
financial limitations and significant side effects. However, 
most of the potential benefits of the current approaches are 
observed only in late DS, but not in the early DS, nor in 
exercise-induced dumping, a condition described that affects 
some post-bariatric athletes,10–12 specially during intense 
physical activities,10,11 whose pathophysiology remains 
uncertain but may be due to exacerbation of gastrointestinal 
physiological adaptions to physical activity.11
Indeed, there is a lack of previous papers focusing on 
the management of exercise-induced DS, except for expert 
opinion and experience and nonscientific recommendations.13 
A recent review on management of DS has been published 
and reinforces the lack of papers about correlations between 
physical activity and DS.4
Acarbose, a glucosidase inhibitor that slows carbohydrate 
digestion and is primarily prescribed as an antidiabetic agent 
has been shown to be effective in late DS,6,14–16 but has not 
been studied for early DS; rationale of protection of late 
dumping by acarbose is based on the fact that this drug delays 
glucose absorption; thus, hyperinsulinemic hypoglycemia 
due to excessive insulin release by incretin and by direct 
glucose stimulation is prevented by acarbose.14,16 Further-
more, acarbose has the potential benefit to prevent beta-cell 
hypertrophy and hyperplasia; indeed, hyperinsulinemic 
hypoglycemia, one of the main cornerstone aspects of DS, 
has a significant improvement by acarbose.6,17,18
Other studies with acarbose in DS have not been per-
formed, as severe side effects such as excessive flatulence14 
had limited its use. Despite the benefits, acarbose has 
not been standardized as part of protocols to manage DS 
symptoms.3
Despite the symptomatic limitations of acarbose, the lack 
of efficient options to prevent and improve DS and the strong 
likelihood of acarbose to improve both early and late DS 
encouraged us to undertake this study. Therefore, we aimed 
to evaluate the role of acarbose in prevention and treatment of 
DS and in resistive exercises resistance in bariatric subjects.
Methods
Selection of subjects
Patients who previously underwent Roux-en-Y gastric 
bypass surgery, achieved body weight goal (body mass 
index <27 kg/m2 for men and <25 kg/m2 for women), had 
a confirmed diagnosis of DS and were refractory to diet 
recommendations were initially selected. Inclusion criteria 
were the complete adherence to an isocaloric (calculated by 
indirect calorimetry) and high protein (1.5–1.8 g/kg/day) 
diet plan, proposed resistive exercises (frequency, intensity, 
and exercise prescription varied among individuals), and 
age between 18 and 80 years. Patients who lacked regular 
follow-up were excluded.
Intervention
Fifty milligrams of acarbose was orally administered 4–5 
times a day before meals for 6 months. For those patients who 
presented with severe flatulence, 120 mg simethicone (b.i.d.) 
was additionally prescribed. The dose of 50 mg before meals 
has been extensively studied and standardized,14–16 whereas 
the addition of simethicone was thought to attenuate the 
most important adverse effects of acarbose use (abdominal 
cramps, bloating, and flatulence).
Evaluated aspects
Multiple patterns of DS were evaluated: 1) number of early 
(0–45 min) DS episodes per week and 2) number of late 
(45–240 min) DS episodes a week. The DS severity evalua-
tion methods were 1) self-referred intensity of each episode: 
rated from 1 (almost asymptomatic) to 10 (loss of conscious), 
2) Sigstad’s scoring system to evaluate diagnosis and intensity 
of DS (shock +5; fainting, syncope, or unconsciousness +4; 
desire to lie down +4; dyspnea +3; weakness +3; sleepiness, 
apathy +3; palpitations +3; restlessness +2; dizziness +2; 
headaches +1; warm, clammy skin, or pallor +1; nausea 
+1; abdominal fullness +1; borborygmus +1; eructation −1; 
vomiting −4), and 3) ability to perform resistive exercises: 
rated from 0 (any effort induces DS symptoms) to 10 (no 
symptoms, even in intensive weight lifting). Subjects were 
prospectively instructed to evaluate and write down the fre-
quency and severity of DS episodes and to bring the results 
at each visit, which happened every 2 weeks for 6 months. 
We proposed that those patients who presented a significant 
improvement of DS symptoms could continue the therapy 
after the end of the study. In each visit, subjects were actively 
queried about missing doses and irregular use.
Ethical approval
The proposed study protocol did not provide new or experi-
mental therapies, but analyzed standardized modalities, and 
therefore approval from an ethics committee was not required. 
The exemption was issued by the national review board and 
ethics committee system (Sistema CEP-CONEP – Plataforma 
 
D
ia
be
te
s,
 M
et
ab
ol
ic 
Sy
nd
ro
m
e 
an
d 
O
be
sit
y:
 T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
20
0.
14
4.
94
.2
3 
on
 0
6-
Au
g-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2016:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
445
Acarbose improves dumping syndrome
Brasil), which has formally authorized the intervention without 
submission to an ethics committee, but required that we provide 
subjects written informed consent to participate in the study, 
and containing all the benefits and possible harmful effects of 
the use of acarbose. We confirm that every patient was fully 
aware of the purpose of the study and signed informed consent 
to participate, prior to beginning the use of acarbose. The prin-
ciples outlined in the Declaration of Helsinki were followed.
Results
A total of 25 subjects (13 men and 12 women; mean age, 37.2 
years) were regularly followed up. None of the patients with-
drew or missed doses. Among these, 7 presented with severe 
flatulence and one patient showed persistent flatulence despite 
simethicone prescription. None of the subjects stopped acar-
bose use owing to side effects. Significant improvements were 
seen in all analyzed parameters: 1) mean number of early DS 
episodes per week (2.18–0.31; 85.8% reduction; p<0.001), 
2) mean number of late DS episodes per week (2.79–0.12; 
95.7% reduction; p<0.001), 3) self-referred intensity of each 
episode (6.1–1.65; 73.0% reduction; p<0.001), 4) Sigstad’s 
score (2.36–0.32; 86.4% reduction; p<0.001), and 5) ability 
to perform resistive exercises (3.03–7.12; 135.0% improve-
ment; p<0.001). These results are summarized in Table 1. 
Improvements were observed from the beginning of the use 
of acarbose and persisted throughout the 6 months of therapy.
Complete remission of DS (except during exercises) was 
observed in 21 patients (84% of analyzed subjects), which 
persisted throughout the 6 months of acarbose use in all 21 
subjects.
Discussion
Bariatric surgery reduces metabolic, cardiovascular, and neo-
plastic risks, overall mortality, and substantially improves the 
quality of life. However, DS has limited the everyday  activities 
of several post-bariatric surgery patients and impaired expected 
improvement in various aspects of quality of living.1,2 Little 
effort has gone into finding effective options to decrease sever-
ity and frequency of DS events; moreover, the frequency of 
severe DS and number of DS-related deaths are likely under 
reported. Acarbose has been shown to be an inexpensive option 
that substantially improves overall quality of life of post-bariat-
ric subjects affected by DS, particularly the late dumping.14–16
Although early DS is not related to hypoglycemia, the 
complete understanding of its pathophysiology is still lack-
ing and is assumed to be due to a contraction of the plasma 
volume as a result of the fluid shifts into the gastrointestinal 
tract,19 which does not fully justify the signs and symptoms 
observed in early dumping. Possibly, the delay of autonomic 
and incretin hormones stimulations (once incretins also 
induce sympathetic and autonomic effects) may at least 
partly explain the improvement observed in early DS; in 
fact, increased release of multiple gastrointestinal hormones, 
including vasoactive agents, incretins, and glucose modula-
tors, in early DS has been described.4,20–22
To the best of our knowledge, the novelties of this study 
are that it has been the first to show 1) the important improve-
ment of early DS and complete remission of DS in most 
patients (84.0%) who were treated with acarbose and 2) the 
improvement of exercise capacity among DS subjects who 
triggered or worsened DS symptoms during physical exer-
tion. Subjective patient testimonies express relevant change 
in everyday life and the desire to maintain long-term therapy.
Regular intake was observed in all included subjects, 
probably due to the benefits provided by this drug. Likewise, 
all patients maintained the use of acarbose after the end of 
the study, once the improvement observed was significant 
that it would be an ethical issue to interrupt the proposed 
therapy. Therefore, we were not able to predict the effects of 
acarbose discontinuation, although some improvement could 
be potentially observed after acarbose discontinuation, given 
the fact that hyperfunction and hypertrophy of the beta-cells, 
related to rapid glucose absorption in bariatric subjects, are 
blunted by this drug.
A limitation of the study is that we did not include a con-
trol group to study the possible placebo effect of acarbose, 
although it is unlikely that the observed improvements are 
due to placebo effect.
Conclusion
Acarbose induced complete remission of DS in most subjects 
and substantially decreased the frequency and intensity of 
both early and late DS events. Further prospective  randomized 
Table 1 Summary of the results
Analyzed parameter Before 
acarbose
After 
6 months 
of acarbose
Change, % 
(p-value)
Mean number of early DS 
episodes/week
2.18 0.31
−85.8 (<0.001)
Mean number of late DS 
episodes/week
2.79 0.12
−95.7 (<0.001)
Mean self-referred intensity 
of each DS episode
6.1 1.65
−73.0 (<0.01)
Sigstad’s scoring 2.36 0.32
−86.4 (<0.001)
Ability to perform resistive 
exercises
3.03 7.12 +135.0 (<0.001)
Abbreviation: DS, dumping syndrome.
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placebo-controlled double-blind clinical trials with monitor-
ing of vital signs and glucose should be performed in order 
to confirm our findings. Until then, acarbose may be treated 
as an option for refractory DS subjects.
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